CPRX News and Press, Catalyst Pharmaceuticals Inc. From 12/05/23

CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100...

2023-12-04 08:22:02 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity Catalyst Pharmaceuticals Non-GAAP EPS of $0.49 beats by $0.48, revenue of $102.7M beats by $2.33M For further details see: Ca...

Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04,...

2023-11-30 07:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that...

2023-11-09 13:04:02 ET Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2023 Results Conference Call November 09, 2023 08:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Steven Miller - Chief Opera...

2023-11-08 16:38:22 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity Catalyst Pharmaceuticals: The Journey From Earnings Euphoria To Patent Perils Catalyst Pharmaceuticals Q3 2023 Earnings Preview ...

Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License Third Quarter...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Catalyst Pharmaceuticals Inc. (CPRX) is expected to report $-0.24 for Q3 2023